Chronic Hepatitis C
Glecaprevir and pibrentasvir are used to treat chronic hepatitis C, which is a long-term viral infection affecting the liver. This combination is effective against multiple genotypes of the virus, making it suitable for a wide range of patients. The treatment aims to clear the virus from the body, reduce liver damage, and prevent complications such as liver cirrhosis, which is scarring of the liver, and liver cancer.
Glecaprevir, a protease inhibitor, blocks an enzyme the virus needs to multiply. Pibrentasvir, an NS5A inhibitor, prevents the virus from assembling and replicating. Together, they stop the virus from multiplying and help the body clear the infection. This combination approach is effective against multiple genotypes of the virus, making it a versatile treatment option for hepatitis C.
The usual adult daily dose for the combination of glecaprevir and pibrentasvir is three tablets taken once a day. Each tablet contains a fixed amount of both medicines, designed to work together to treat hepatitis C. It's important to take the medication exactly as prescribed by a healthcare provider to ensure its effectiveness. Both medicines are combined in a single tablet to simplify the dosing regimen and improve adherence to the treatment plan.
The most common side effects of glecaprevir and pibrentasvir include fatigue, headache, and nausea. These effects are generally mild and tend to improve as the body adjusts to the medication. In rare cases, more significant adverse effects like liver problems can occur, especially in patients with pre-existing liver conditions. Both medicines share these side effects due to their action on the liver and the body's response to clearing the virus.
Glecaprevir and pibrentasvir should not be used in patients with severe liver impairment, as this can worsen their condition. Patients with a history of hepatitis B should be monitored closely, as the virus can reactivate during treatment. Both medicines can interact with other drugs, so it's important to inform healthcare providers about all medications being taken. Regular monitoring of liver function is recommended to ensure safety during treatment.
US(FDA), UK(BNF)
YES
NO
Hepatitis C Virus NS5A Inhibitor
NO